While MYD88/CD79B double-mutant ABC might be amenable to targeted therapy by BTK inhibitors such as ibrutinib, further studies are needed to define the best therapeutic strategy for isolated CD79B or MYD88-mutant DLBCLs. The gene discussed is MYD88; the disease is aneurysmal bone cyst.